Mice lacking Glrx develop MASLD (fatty liver, obesity, dyslipidemia) with a regular diet, while adenoviral Glrx gene transfer activates SirT1 and reverses steatosis (147). The gene discussed is GLRX; the disease is metabolic dysfunction-associated steatotic liver disease.